{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:14:15Z","timestamp":1788585255676,"version":"build-2803163510"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA035246, R01DA040644, R01DA042751, R34DA042926, T32DA007209"],"award-info":[{"award-number":["R01DA035246, R01DA040644, R01DA042751, R34DA042926, T32DA007209"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00704","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:43:04Z","timestamp":1569458584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans"],"prefix":"10.3389","volume":"10","author":[{"given":"Kelly E.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia L.","family":"Bergeria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6","article-title":"Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study","volume":"387","author":"Berterame","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11916-018-0689-1","article-title":"Global supply and demand of opioids for pain management","volume":"22","author":"Kunnumpurath","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2016.0414","article-title":"Pain treatment continues to be inaccessible for many patients around the globe: second phase of opioid price watch, a cross-sectional study to monitor the prices of opioids","volume":"20","author":"Pastrana","year":"2017","journal-title":"J Palliative Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.03.015","article-title":"Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006","volume":"47","author":"Duthey","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"B5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jpainsymman.2013.12.237","article-title":"Cross-sectional pilot study to monitor the availability, dispensed prices, and affordability of opioids around the globe","volume":"48","author":"De Lima","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"B6","article-title":"Availability and utilization of opioids for pain management: global issues","volume":"14","author":"Manjiani","year":"2014","journal-title":"Ochsner J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00365-4","article-title":"Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries","volume":"17","author":"Vranken","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/J354v16n01_09","article-title":"Opiophobia as a barrier to the treatment of pain","volume":"16","author":"Bennett","year":"2002","journal-title":"J Pain Palliative Care Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2017-0043","article-title":"Undertreatment of pain and low use of opioids in Latin America","volume":"8","author":"Garc\u00eda","year":"2018","journal-title":"Pain Manag"},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.20452\/pamw.4167","article-title":"Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain","volume":"128","author":"Graczyk","year":"2018","journal-title":"Pol Arch Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihy002","article-title":"Barriers to the availability and accessibility of controlled medicines for chronic pain in Africa","volume":"10","author":"Nchako","year":"2018","journal-title":"Int Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e328363d163","article-title":"Principles of assessment of abuse liability: US legal framework and regulatory environment","volume":"24","author":"Rocha","year":"2013","journal-title":"Behav Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.07.035","article-title":"Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations","volume":"153","author":"Comer","year":"2012","journal-title":"Pain"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100492","article-title":"Assessing abuse liability during drug development: changing standards and expectations","volume":"83","author":"Schoedel","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01745.x","article-title":"The necessity and utility of abuse liability evaluations in human subjects","volume":"86","author":"Vocci","year":"1991","journal-title":"Br J Addict"},{"key":"B16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2016_448","article-title":"The abuse potential of prescription opioids in humans\u2014closing in on the first century of research","volume-title":"Non-medical and illicit use of psychoactive drugs","author":"Walsh","year":"2016"},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD009574","DOI":"10.1002\/14651858.CD009574.pub2","article-title":"Tramadol for postoperative pain treatment in children","volume":"18","author":"Schnabel","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-017-2310-x","article-title":"Adjuncts to local anaesthetics in tonsillectomy: a systematic review and meta-analysis","volume":"31","author":"Vlok","year":"2017","journal-title":"J Anesthesia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1354821","article-title":"The role of tramadol in pain management in Latin America: a report by the change pain Latin America advisory panel","volume":"33","author":"Santos Garcia","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S162296","article-title":"Tramadol: a valuable treatment for pain in Southeast Asian countries","volume":"11","author":"Vijayan","year":"2018","journal-title":"J Pain Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","author":"Grond","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B22","article-title":"Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an \u2018atypical\u2019 opioid analgesic","volume":"260","author":"Raffa","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"B23","article-title":"Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol","volume":"267","author":"Raffa","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0801(199801\/02)12:1<13::AID-BMC712>3.3.CO;2-R","article-title":"Determination of cis and trans isomers of tramadol hydrochloride by capillary zone electrophoresis","volume":"12","author":"Guo","year":"1998","journal-title":"Biomed Chromatogr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13788.x","article-title":"Effects of the central analgesic tramadol and its main metabolite, o-desmethyltramadol, on rat locus coeruleus neurones","volume":"110","author":"Sevcik","year":"1993","journal-title":"Br J Pharmacol"},{"key":"B26","article-title":"Influence of tramadol on neurotransmitter systems of the rat brain","volume":"46","author":"Frink","year":"1996","journal-title":"Arzneimittel-Forschung"},{"key":"B27","article-title":"Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids","volume":"38","author":"Hennies","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9489-8","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on \u03bc-opioid agonism and monoamine reuptake inhibition, in the rat","volume":"25","author":"Beier","year":"2008","journal-title":"Pharm Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2006.11.003","article-title":"Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype","volume":"55","author":"Garc\u00eda-Quetglas","year":"2007","journal-title":"Pharmacol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/chir.20360","article-title":"Route-dependent stereoselective pharmacokinetics of tramadol and its active o-demethylated metabolite in rats","volume":"19","author":"Parasrampuria","year":"2007","journal-title":"Chirality"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.14.2.109","article-title":"Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans","volume":"14","author":"Carroll","year":"2006","journal-title":"Exp Clin Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0847-3","article-title":"Modest opioid withdrawal suppression efficacy of oral tramadol in humans","volume":"194","author":"Lofwall","year":"2007","journal-title":"Psychopharmacology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00482-3","article-title":"The antinociceptive effect of tramadol on a model of neuropathic pain in rats","volume":"66","author":"Apaydin","year":"2000","journal-title":"Life Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2125.1996.tb00152.x","article-title":"Contribution of monoaminergic modulation to the analgesic effect of tramadol","volume":"41","author":"Desmeules","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1838","article-title":"Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial","volume":"9","author":"Dunn","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1919-3","article-title":"Physical dependence potential of daily tramadol dosing in humans","volume":"211","author":"Lanier","year":"2010","journal-title":"Psychopharmacology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.05.010","article-title":"Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial","volume":"133","author":"Lofwall","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2012.735216","article-title":"Topical review on the abuse and misuse potential of tramadol and tilidine in Germany","volume":"34","author":"Radbruch","year":"2013","journal-title":"Subst Abuse"},{"key":"B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jaac.2012.11.014","article-title":"Characterization of adolescent prescription drug abuse and misuse using the researched abuse diversion and addiction-related surveillance (RADARS\u00ae) system","volume":"52","author":"Zosel","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)31073-0","article-title":"Tramadol: Africa\u2019s opioid crisis","volume":"391","author":"Salm-Reifferscheidt","year":"2018","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.31389\/jied.10","article-title":"Drug problem or medicrime? Distribution and use of falsified tramadol medication in Egypt and West Africa","volume":"1","author":"Klein","year":"2019","journal-title":"J Illicit Econ Dev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2015.1014959","article-title":"Adolescent tramadol use and abuse in Egypt","volume":"41","author":"Bassiony","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000380","article-title":"Opioid use disorders attributed to tramadol among Egyptian university students","volume":"12","author":"Bassiony","year":"2018","journal-title":"J Addict Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsycho.2006.01.010","article-title":"Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol","volume":"73","author":"Epstein","year":"2006","journal-title":"Biol Psychol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ajmg.b.20057","article-title":"Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction","author":"Compton","year":"2003","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.181131","article-title":"Discriminative stimulus effects of tramadol in humans","volume":"338","author":"Duke","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jeab.137","article-title":"Mu opioid mediated discriminative-stimulus effects of tramadol: an individual subjects analysis","volume":"103","author":"Strickland","year":"2015","journal-title":"J Exp Anal Behav"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.09.018","article-title":"Abuse liability and reinforcing efficacy of oral tramadol in humans","volume":"129","author":"Babalonis","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"B49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/00003495-199400471-00007","article-title":"Acute effects of tramadol in methadone-maintained volunteers","volume":"47","author":"Cam\u00ed","year":"1994","journal-title":"Drugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2016.0361","article-title":"Assessment of abuse liability of tramadol among experienced drug users: double-blind crossover randomized controlled trial","volume":"12","author":"Das","year":"2016","journal-title":"J Opioid Manag"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0376-8716(91)90081-9","article-title":"Abuse potential and pharmacological comparison of tramadol and morphine","volume":"27","author":"Preston","year":"1991","journal-title":"Drug Alcohol Depend"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2739-4","article-title":"Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment","volume":"223","author":"Stoops","year":"2012","journal-title":"Psychopharmacology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.007","article-title":"Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users","volume":"80","author":"Zacny","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2009.0022","article-title":"Relationship between rate of infusion and reinforcing strength of oxycodone in humans","volume":"5","author":"Comer","year":"2009","journal-title":"J Opioid Manag"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01754.x","article-title":"Pharmacokinetic considerations in abuse liability evaluation","volume":"86","author":"Farre","year":"1991","journal-title":"Br J Addict"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e3283644d15","article-title":"Escalation of drug self-administration as a hallmark of persistent addiction liability","volume":"24","author":"Edwards","year":"2013","journal-title":"Behav Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E577","article-title":"Tramadol exposures reported to statewide poison control system","volume":"39","author":"Marquardt","year":"2005","journal-title":"Ann Pharmacother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1177\/0960327108090270","article-title":"Tramadol intoxication: a review of 114 cases","volume":"27","author":"Shadnia","year":"2008","journal-title":"Hum Exp Toxicol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.yrtph.2015.06.009","article-title":"Preclinical assessment of abuse liability of biologics: in defense of current regulatory control policies","volume":"73","author":"Gauvin","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2014.03.003","article-title":"Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose","volume":"238","author":"Bastami","year":"2014","journal-title":"Forensic Sci Int"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0920-y","article-title":"The effects of tramadol on static and dynamic pupillometry in healthy subjects\u2014the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status","volume":"61","author":"Fliegert","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256239","article-title":"Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics","volume":"11","author":"Gan","year":"2007","journal-title":"Mol Diagnosis Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.047779","article-title":"Pharmacokinetic\/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity","volume":"305","author":"Garrido","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/JCP.0b013e318160f827","article-title":"Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol","volume":"28","author":"Kirchheiner","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"B65","article-title":"Miotic action of tramadol is determined by CYP2D6 genotype","volume":"56","author":"Slana\u0159","year":"2007","journal-title":"Physiol Res"},{"key":"B66","article-title":"Effect of the cytochrome P450 2D6* 10 genotype on the pharmacokinetics of tramadol in post-operative patients","volume":"69","author":"Xu","year":"2014","journal-title":"Pharmazie"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:43:09Z","timestamp":1569458589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":67,"alternative-id":["10.3389\/fpsyt.2019.00704"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00704","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]},"article-number":"704"}}